Silexion Therapeutics Ltd. (SLXN) Earnings History
Annual and quarterly earnings data from 2020 to 2025
Loading earnings history...
SLXN EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
SLXN Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export SLXN earnings history in CSV or JSON format
Free sign-in required to download data
Silexion Therapeutics Ltd. (SLXN) Earnings Overview
As of May 8, 2026, Silexion Therapeutics Ltd. (SLXN) reported trailing twelve-month net income of -$12M, reflecting -239.4% year-over-year growth. The company earned $-3.81 per diluted share over the past four quarters.
Looking at the long-term picture, SLXN's historical earnings data spans multiple years. The company achieved its highest annual net income of -$195,860 in fiscal 2020.
Silexion Therapeutics Ltd. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SRPT ($65M net income, -32.5% margin), ARWR (-$301M net income, -0.2% margin), NTLA (-$413M net income, -609.9% margin), SLXN has comparable earnings metrics. Compare SLXN vs SRPT →
SLXN Earnings vs Peers
Earnings metrics vs comparable public companies
SLXN Historical Earnings Data (2020–2025)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$12M | +27.6% | -$12M | $-8.96 | - | - |
| 2024 | -$16M | -232.7% | -$13M | $-2.64 | - | - |
| 2023 | -$5M | -53.7% | -$5M | $-4.42 | - | - |
| 2022 | -$3M | -325.7% | -$4M | $0.03 | - | - |
| 2021 | $-755,218 | -285.6% | $-943,933 | $-0.05 | - | - |
| 2020 | $-195,860 | - | $-195,860 | $-0.01 | - | - |
See SLXN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SLXN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SLXN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSLXN — Frequently Asked Questions
Quick answers to the most common questions about buying SLXN stock.
Is SLXN growing earnings?
SLXN EPS fell to $-3.81, with earnings declining -239.4%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-12M.
What are SLXN's profit margins?
Silexion Therapeutics Ltd. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are SLXN's earnings?
SLXN earnings data spans 2020-2025. The declining earnings trend is -239.4% YoY. Historical data enables comparison across business cycles.